Faron Pharmaceuticals Ltd. has announced that its CEO, Dr. Markku Jalkanen, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference in New York City on September 12, 2023. The company will also be available for one-on-one meetings with investors. The presentation will take place at 10:30 a.m. ET in Room Holmes I, 4th floor. Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. Its lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody being investigated in Phase I/II clinical trials for hematological cancers.